Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues

Eur J Pharmacol. 2020 Feb 5:868:172793. doi: 10.1016/j.ejphar.2019.172793. Epub 2019 Nov 16.

Authors

Peter Ferdinandy¹, Fumio Yoneda², Shizuko Muraoka², Susanna Fürst³, Klara Gyires³, Ildiko Miklya⁴

Affiliations

¹ Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary; Pharmahungary Group, Szeged, Hungary.
² Fujimoto Pharmaceutical Corporation, Osaka, Japan.
³ Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary.
⁴ Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary. Electronic address: miklya.ildiko@med.semmelweis-univ.hu.

PMID: 31743738
DOI: 10.1016/j.ejphar.2019.172793

Abstract

In memoriam of Joseph Knoll: the selegiline story continues.

Keywords: BPAP; Enhancer regulation; Geroprotection; Longevity; Selegiline/(−)-deprenyl; Tumor-manifestation-suppressing effect.

Copyright © 2019. Published by Elsevier B.V.

Publication types

Historical Article

MeSH terms

Aging
Brain / drug effects
Brain / pathology
Drug Development / history
Geriatrics / methods
Geriatrics / trends*
History, 20th Century
Humans
Life Expectancy / trends*
Monoamine Oxidase Inhibitors / pharmacology
Monoamine Oxidase Inhibitors / therapeutic use*
Neurodegenerative Diseases / drug therapy*
Neurodegenerative Diseases / epidemiology
Neurodegenerative Diseases / pathology
Selegiline / pharmacology
Selegiline / therapeutic use*

Substances

Monoamine Oxidase Inhibitors
Selegiline

Personal name as subject

Joseph Knoll